HomeTrialNCT06799286
🔬NCT06799286Phase 1ACTIVE NOT RECRUITING

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

Study Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment10 participants
Primary Completion
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.746682+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.